Technical Analysis for TGTX - TG Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | 5.74% | |
| Lower Bollinger Band Walk | Weakness | 5.74% | |
| Multiple of Ten Bullish | Other | 5.74% | |
| Lower Bollinger Band Walk | Weakness | 13.12% | |
| Stochastic Reached Oversold | Weakness | 13.12% | |
| Lower Bollinger Band Touch | Weakness | 13.12% | |
| Oversold Stochastic | Weakness | 13.12% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2020
- Sector: Healthcare
- Industry: Biotechnology
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
Biopharmaceutical Cancer Treatment Of Cancer Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.76 |
| 52 Week Low | 4.95 |
| Average Volume | 1,693,258 |
| 200-Day Moving Average | 14.24 |
| 50-Day Moving Average | 20.22 |
| 20-Day Moving Average | 20.63 |
| 10-Day Moving Average | 20.19 |
| Average True Range | 1.33 |
| ADX | 18.13 |
| +DI | 25.55 |
| -DI | 25.31 |
| Chandelier Exit (Long, 3 ATRs ) | 19.46 |
| Chandelier Exit (Short, 3 ATRs ) | 21.67 |
| Upper Bollinger Band | 22.95 |
| Lower Bollinger Band | 18.31 |
| Percent B (%b) | 0.7 |
| BandWidth | 22.50 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.0495 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.64 | ||||
| Resistance 3 (R3) | 23.42 | 22.50 | 23.29 | ||
| Resistance 2 (R2) | 22.50 | 21.97 | 22.61 | 23.17 | |
| Resistance 1 (R1) | 22.03 | 21.64 | 22.27 | 22.25 | 23.06 |
| Pivot Point | 21.11 | 21.11 | 21.23 | 21.22 | 21.11 |
| Support 1 (S1) | 20.64 | 20.58 | 20.88 | 20.86 | 20.04 |
| Support 2 (S2) | 19.72 | 20.25 | 19.83 | 19.93 | |
| Support 3 (S3) | 19.25 | 19.72 | 19.81 | ||
| Support 4 (S4) | 19.47 |
